AstraZeneca: Depression trials
The registry lists 29 Depression studies with AstraZeneca as lead sponsor. 0 are open to participants now and 11 have results posted.
Phase 1 3Phase 2 4Phase 3 15No phase 7(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder.CompletedNCT01197508Phase 3Results posted
- A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive DisorderCompletedNCT01180400Phase 3Results posted
- A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder (MDD)CompletedNCT01157078Phase 3Results posted
- A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive DisorderCompletedNCT01153347Phase 3Results posted
- A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive DisorderCompletedNCT01152554Phase 3Results posted
- 6-week Study Treatment to Evaluate the Safety and Effectiveness of AZD2066 in Patients With Major Depressive DisorderTerminatedNCT01145755Phase 2Results posted
- AZD7268 Safety and Tolerability StudyCompletedNCT01020799Phase 2Results posted
- Efficacy and Safety of Quetiapine Versus Quetiapine Plus Lithium in Bipolar DepressionCompletedNCT00883493Phase 3Results posted
- Pediatric Bipolar DepressionCompletedNCT00811473Phase 3Results posted
- Comparing Quetiapine XR Monotherapy and Augmentation With Lithium Augmentation in TRD PatientsCompletedNCT00789854Phase 3Results posted
- Quetiapine Extended Release Depression SymptomsCompletedNCT00640562Phase 3Results posted
- Retrospective Observational Study DIANA StudyCompletedNCT01976793
- Prevalence and Risk Factors in Unipolar Depression Patients Without Remission After One Antidepressant TrialCompletedNCT01887639
- Atypical Antipsychotics in the Treatment of Affective Symptoms of Schizophrenia in HungaryCompletedNCT01534936
- Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4451CompletedNCT01196676Phase 1
- Study Where Pharmaco Magnetic Resonance Imaging (MRI) Effects of AZD6765 Will be Compared to Placebo in Depressive Male and Female SubjectsCompletedNCT01046630Phase 1
- Observational Study to Evaluate Bipolar Disorder Symptoms in Patients Presented With Schizophrenia or DepressionCompletedNCT01028196
- Positron Emission Tomography (PET) Study With [11C]Raclopride to Determine Central D2 Dopamine Occupancy of SEROQUELCompletedNCT00832221Phase 1
- Antidepressant Incomplete Response DepressionCompletedNCT00782964
- Four Dimensions in SchizophreniaCompletedNCT00782899
- AZD6765 Severe Major Depressive Disorder (MDD) IVCompletedNCT00781742Phase 2
- Depressive Symptoms in Acute Manic EpisodeCompletedNCT00690248
- AZD6765 for Treatment Resistant DepressionCompletedNCT00491686Phase 2
- Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in the Treatment of Major Depressive DisordersCompletedNCT00326144Phase 3
- Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in Combination With an Antidepressant in the Treatment of Major Depressive DisordersCompletedNCT00326105Phase 3
- Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo and Active Control in Major Depressive DisorderCompletedNCT00321490Phase 3
- Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo in Major Depressive DisorderCompletedNCT00320268Phase 3
- Seroquel in Bipolar Depression Versus LithiumCompletedNCT00206141Phase 3
- Seroquel in Bipolar Depression Versus SSRICompletedNCT00119652Phase 3